プロモーションスケジュール Regulus Therapeutics Inc.
詳細なスケジュール
簡易グラフ
会社について Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. さらに詳しく| IPO date | 2012-10-04 |
|---|---|
| ISIN | US75915K3095 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.regulusrx.com |
| Цена ао | 2.85 |
| 1日あたりの価格変動: | -3.75% (1.6) |
|---|---|
| 週ごとの価格変動: | -3.14% (1.59) |
| 月ごとの料金変更: | -6.1% (1.64) |
| 3ヶ月間の価格変動: | -4.35% (1.61) |
| 半年間の価格変動: | -12.5% (1.76) |
| 年間の価格変動: | +20.31% (1.28) |
| 3年間の価格推移: | +358.06% (0.3362) |
| 5年間の価格推移: | +110.96% (0.73) |
| 10年間の価格推移: | 0% (1.54) |
| 年初からの価格変動: | +4.76% (1.47) |
|
|
過小評価
|
効率
|
|||||||||||||||||||||||||||||||||||||
配当金
|
義務
|
成長の衝動
|
|||||||||||||||||||||||||||||||||||||
| 機関 | 音量 | 共有, % |
|---|---|---|
| Federated Hermes, Inc. | 3875578 | 5.92 |
| FMR, LLC | 2922600 | 4.46 |
| NEA Management Company, LLC | 1945579 | 2.97 |
| DAFNA Capital Management, LLC | 1111049 | 1.7 |
| Vanguard Group Inc | 286431 | 0.44 |
| Victory Capital Management Inc. | 271736 | 0.42 |
| Sarissa Capital Management, LP | 185183 | 0.28 |
| Exome Asset Management LLC | 178404 | 0.27 |
| Geode Capital Management, LLC | 122521 | 0.19 |
| Renaissance Technologies, LLC | 54600 | 0.08 |
| ETF | 共有, % | 年間の利益率, % | 配当金, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.02905 | 17.09 | 1.54048 |
| Avantis U.S Small Cap Equity ETF | 0.00491 | 27.77 | 1.68271 |
ProShares UltraPro Russell2000
|
0.00248 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.00063 | 5.92 | 1.47892 |
| Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Vanguard Russell 2000 Growth ETF | 0 | 23.05 | 0.60264 |
| スーパーバイザー | 役職 | 支払い | 生年 |
|---|---|---|---|
| Mr. Joseph P. Hagan M.B.A. | CEO & Director | 958.23k | 1969 (56 年) |
| Ms. Crispina Calsada CPA | Chief Financial Officer | 579.3k | 1970 (55 年) |
| Mr. Christopher Ray Aker J.D. | Senior VP, General Counsel & Corporate Secretary | 575.94k | 1961 (64 年) |
| Mr. Daniel J. Penksa | VP of Finance & Controller | N/A | 1986 (39 年) |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations | N/A | |
| Dr. Rekha Garg M.D., M.S. | Chief Medical Officer | N/A | |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director | N/A | 1969 (56 年) |
| Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine | N/A |
住所: United States, San Diego. CA, 4224 Campus Point Court - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.regulusrx.com
Webサイト: https://www.regulusrx.com
